Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Kabra Drugs Limited has informed BSE that the audited financial results for the quarter and full year ended 31 March 2025 were published in newspapers as required under SEBI's Listing Regulations. The extract was published in Free Press (English) and Chouthasansar (Hindi) on 6 June 2025. Key numbers from the extract show total income of Rs 64.02 lakhs for Q4 FY25, with a net profit of Rs 39.36 lakhs compared to a net loss of Rs 37.07 lakhs in the previous financial year. Equity share capital stood at Rs 450.79 lakhs and reserves at Rs 2,370.79 lakhs, with basic EPS of Rs 0.21 against a negative Rs 0.64 earlier. This is a routine compliance filing confirming the results have been made publicly available through newspaper advertisement.
This is a procedural compliance notice, not a new announcement — the underlying audited results were already approved by the Board earlier. However, the figures do indicate a swing from loss to profit year-on-year, which is mildly positive for shareholders. No immediate share price catalyst expected from this disclosure alone.